Welcome to the DermTech newsroom. Here you’ll find up-to-date information about the company, including our latest press releases, media coverage, events and our blog.
An Interview with Dr. Dan Siegel, Co-Author of the Recent Publication in JAMA Dermatology, “Economic Analysis of a Noninvasive Molecular Pathologic Assay for Pigmented Skin Lesions”
What was the background for this Health Economic study? The current standard of care pathway for assessing pigmented skin lesions suspicious of melanoma is visual assessment followed by surgical biopsy and histopathology.read more
By Dr. Samantha Robare, Board certified Dermatologist, Houston Skin Specialists | Summer provides an excellent opportunity to discuss the importance of regular skin monitoring. When skin cancers, including melanoma, are diagnosed and treated early, cure rates are very high.read more
By Dr. Maral Skelsey, Director of the Dermatologic Surgery Center of Washington and Director of the Mohs Surgery Unit at Georgetown University | As I was about to open the door of the exam room, my nurse handed me a box of tissues. “Take these to the patient,” she said. “ She’s just about used up the box that’s in there.”read more
Management of atypical pigmented lesions involves ruling-out melanoma via a visual assessment followed by surgical biopsy and histopathology. Ideally, when melanomas are identified, they are found at the earliest stages (Melanoma in Situ (MIS)/Stage 1a) when a high cure rate is possible by wide excision.read more
Atypical Nevi Are Not All Precancerous by Gary L. Peck, M.D. | January 8, 2018 No one wants to miss a melanoma when examining a patient. Since severely atypical nevi and early melanomas may be indistinguishable on clinical exam, no one wants to leave such...read more